Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Abstract

Evidence that uncharged verapamil inhibits myocardial contractility.

L Cohen, D Vereault, J A Wasserstrom, G S Retzinger and F J Kezdy
Journal of Pharmacology and Experimental Therapeutics August 1987, 242 (2) 721-725;
L Cohen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Vereault
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J A Wasserstrom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G S Retzinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F J Kezdy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The object of this study was to determine the molecular species of verapamil (Vp) which is responsible for the negative inotropic activity of the drug. Toward this end, we developed a model system which allowed us to determine the concentrations of protonated and neutral Vp and four congeners in solution and bound to an amphiphilic interface. We then determined the effect of Vp and these congeners on twitch tension in sheep trabecular muscle and correlated species abundance with biologic activity. The cumulative log dose-response curves of Vp, acyano-Vp and nor-Vp were sigmoidal. The concentrations of drug which were required to inhibit twitch tension by 50% (IC50) were 1000 +/- 240, 3350 +/- 620 and 7140 +/- 950 nM, respectively (mean +/- S.D.; P less than .01). Quaternary-Vp, an amphiphilic, nonionizable protonated derivative, produced some nonspecific inhibition which never reached 50%. Tetrahydroxy-Vp, a hydrophilic ionizable derivative, was inactive. Concentrations of the membrane-bound, neutral form of Vp, acyano-Vp and nor-Vp were comparable at their IC50 values (86 +/- 19, 104 +/- 19 and 121 +/- 16 nM, respectively; mean +/- S.D.; P, N.S.). In contrast, the concentrations of the membrane-bound, protonated form were significantly different and accounted for the "apparent" difference in the IC50 values. Based on these data, we conclude that: 1) ionizability and amphiphilicity are required for the negative inotropic effects of verapamil, acyano-Vp and nor-Vp; 2) twitch tension correlates best with the concentration of the membrane-bound neutral form of each drug; and 3) the potency differences between Vp, acyano-Vp and nor-Vp, as reflected by their IC50 values, are apparent, not real.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 242, Issue 2
1 Aug 1987
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evidence that uncharged verapamil inhibits myocardial contractility.
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Evidence that uncharged verapamil inhibits myocardial contractility.

L Cohen, D Vereault, J A Wasserstrom, G S Retzinger and F J Kezdy
Journal of Pharmacology and Experimental Therapeutics August 1, 1987, 242 (2) 721-725;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Evidence that uncharged verapamil inhibits myocardial contractility.

L Cohen, D Vereault, J A Wasserstrom, G S Retzinger and F J Kezdy
Journal of Pharmacology and Experimental Therapeutics August 1, 1987, 242 (2) 721-725;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics